How Long Does the Influenza Vaccine Last?

Protection from the seasonal flu shot begins to decline within weeks of vaccination and, for most people, drops substantially over the course of three to six months. The speed of that decline depends on your age, which flu strains are circulating, and what type of vaccine you received. That timeline is why public health agencies push annual revaccination, but the details of how and why protection erodes are more nuanced than “get your shot every fall” suggests.

How Quickly Protection Fades

The clearest picture of intraseason waning comes from large observational studies that track how vaccinated people fare at different points after their shot. One U.S. study found that compared with people tested just two to six weeks after vaccination, those tested about five months or more after their shot had roughly double the odds of testing positive for influenza. The increase was steady and roughly linear: for every additional four weeks since vaccination, the odds of a positive flu test rose by about 16 percent.¹ That pattern held across flu types and was not seen for respiratory syncytial virus tested in the same population, which makes a strong case that the decline is specific to flu immunity rather than some quirk of the study design.

A systematic review and meta-analysis pooling data from multiple seasons found a statistically significant drop in vaccine effectiveness between the first three months after vaccination and the three-to-six-month window. The decline was steepest for A(H3N2), with effectiveness falling by about 33 percentage points between those two periods. Influenza B dropped by about 19 points, and A(H1N1) showed a smaller, non-significant decline of around 8 points.² In practical terms, if you were vaccinated in early September and a late-peaking season drags into March or April, you may have meaningfully less protection by the tail end of flu season than you did at its start.

Why A(H3N2) Is the Worst Offender

A(H3N2) is the flu subtype that causes the most severe seasons in older adults, and it is also the one against which vaccine protection fades fastest. The meta-analysis cited above consistently found lower effectiveness estimates for A(H3N2) at every time point compared with A(H1N1) and influenza B.² Part of the reason is that H3N2 viruses mutate rapidly and are particularly prone to mismatch with the vaccine strain selected months earlier. But even when the match is decent, protection against H3N2 still drops faster than against other strains. Simulation studies estimated that monthly declines in measured vaccine effectiveness ranged as high as roughly 13 percent for H3N2, compared with about 9 percent for H1N1 and 7 percent for B in certain season-age-group combinations.³

This matters because H3N2-dominant seasons tend to be the ones with the highest hospitalization and death rates, especially among people over 65. So the subtype where waning protection would hurt the most is precisely the one where it wanes fastest.

Not All Measured Waning Is Real Waning

Researchers have increasingly recognized that some of the decline we observe in vaccine effectiveness over time may not reflect a true loss of immune protection. A modeling study examined how “leaky” vaccines, meaning vaccines that reduce your chance of infection with each exposure rather than blocking it outright, could create the statistical appearance of waning even if immune protection stayed constant. When a vaccinated person faces repeated exposures across a long season, the cumulative chance of eventually getting infected grows, and that looks like waning in observational data. The study estimated this artifact could account for roughly 15 to 53 percent of the observed decline in effectiveness, depending on the infection rate and flu strain.³

This does not mean waning is an illusion. Antibody levels genuinely decline after vaccination. But it does mean that the apparent speed of decline in real-world studies slightly overstates the actual immunological erosion. The true picture is a mix of genuinely fading antibodies and the statistical inevitability that leaky protection gets “used up” when enough virus is circulating. In seasons with low infection rates, measured waning was minimal, dropping by less than one percentage point per month, while in high-infection seasons the observed decline was several times larger.³

Antibodies Versus Protection

There is an important distinction between how long your antibodies last and how long you are effectively protected. Antibody levels measured in the blood decline slowly after flu vaccination. One study tracking people who received inactivated flu vaccines found that it took more than 600 days for antibody levels to drop by half, regardless of the flu strain targeted.⁴ That sounds reassuring, but it does not translate into two years of protection. The reason is that a 50 percent drop from a high peak may still leave you above a protective threshold, while the same proportional decline from a modest peak could leave you below it. People who mounted a strong initial antibody response tended to see the fastest absolute declines, though they often remained above protective levels longer simply because they started higher.

For immunocompromised people, the picture is bleaker. A review of adaptive immunity across respiratory viruses found that influenza immunity in immunocompromised patients tends to fade within about six months.⁵ This is partly why high-dose vaccine formulations were developed for vulnerable groups.

Older Adults Lose Protection Faster

Aging reshapes the immune response in ways that hit flu vaccine durability especially hard. Older adults produce weaker T-cell responses to the vaccine, and those T cells are less functionally versatile. One study found that adults over 65 had significantly lower frequencies of flu-specific helper T cells after vaccination, and those T cells showed reduced polyfunctionality, meaning they were less capable of performing the multiple immune tasks needed to fight infection effectively. That impaired T-cell response correlated with lower antibody levels as well.⁶

The practical consequence is stark. In modeling based on multiple flu seasons, vaccine effectiveness in hospitalized older adults waned by roughly 10 to 11 percent per month, compared with about 8 to 9 percent per month across all adults. By five to six months after vaccination, effectiveness approached zero.⁷ High-dose flu vaccines were designed to counteract this problem by delivering four times the antigen of a standard shot, provoking a stronger initial immune response that takes longer to fall below protective thresholds. A meta-analysis spanning over 45 million people aged 65 and older across 12 flu seasons confirmed that high-dose vaccines provided significantly better protection than standard-dose versions against flu-like illness and flu-related hospitalization, regardless of the dominant circulating strain.⁸

Similar benefits have been shown for immunocompromised patients. A meta-analysis of randomized trials found that high-dose flu vaccine produced stronger antibody responses across all vaccine strains in immunocompromised recipients compared with standard doses.⁹

Children and First-Time Vaccination

Young children who are getting the flu vaccine for the first time face a different durability challenge. Because they lack prior immune memory to influenza, a single dose gives them less robust protection that fades faster. A cohort study of children aged 6 to 23 months who received only one dose of flu vaccine found that effectiveness was about 74 percent in the first three months but dropped to about 55 percent by four months and was not statistically significant beyond five months.¹⁰ This is why guidelines in many countries recommend two doses, spaced a month apart, for children being vaccinated for the first time.

A meta-analysis comparing one versus two doses in first-season children found that a single dose provided about 31 percent pooled effectiveness while two doses reached about 43 percent. Among children under three, the gap widened considerably: one dose offered only about 14 percent effectiveness (not statistically distinguishable from zero), whereas two doses still provided around 41 percent protection.¹¹ The second dose does not just boost protection; it may also help it last longer by more thoroughly priming the immune system.

How Long Maternal Vaccination Protects Newborns

Babies under six months are too young to be vaccinated themselves, so their primary defense against flu comes from antibodies transferred from their mother during pregnancy. The timing of vaccination during pregnancy matters a great deal for how much protection reaches the infant. A pooled analysis of three randomized trials found that maternal vaccination was about 56 percent effective at preventing lab-confirmed flu in infants during their first two months of life. That dropped to about 46 percent through four months, and by four to six months the protection was no longer statistically significant.¹²

Third-trimester vaccination appears to deliver antibodies to the baby most efficiently. One study found that infants born to mothers vaccinated in the second or third trimester had significantly higher antibody levels at birth compared with infants of unvaccinated mothers, but first-trimester vaccination did not produce a significant difference.¹³ A multi-site study found that maternal vaccination in the third trimester reduced flu-related emergency visits and hospitalizations in infants younger than six months by about 52 percent, compared with only about 17 percent when mothers were vaccinated earlier.¹⁴ The logic is straightforward: antibodies transferred across the placenta are at their freshest when the interval between vaccination and birth is shortest.

Does Yearly Vaccination Make Each Shot Less Effective?

A concern that surfaces regularly is whether getting vaccinated every single year eventually dulls the immune response. There is some evidence that consecutive vaccination modestly reduces effectiveness for certain strains. A systematic review found that people vaccinated in both the current and previous seasons had slightly lower protection compared with those vaccinated only in the current season: about 9 percentage points lower for A(H1N1), 18 points lower for A(H3N2), and 7 points lower for influenza B.¹⁵ The effect was most pronounced for H3N2, and the certainty of these estimates was rated low.

Critically, the same review found that being vaccinated in both seasons still provided substantially better protection than not being vaccinated at all. The repeat-vaccination effect is a relative dimming, not an erasure. Antibody studies in healthcare workers who received the same H1N1 strain for five consecutive years showed that baseline (pre-shot) antibody levels climbed over time, suggesting the immune system was retaining memory, but the peak boost after each new shot got smaller with each round.¹⁶ When researchers tried to disentangle these effects from intraseason waning, they found that repeat vaccinees were still slightly more likely to test positive for H3N2, but not for H1N1 or B.¹⁷ So the repeat-vaccination issue is real but narrow: it is mostly an H3N2 problem, and skipping vaccination is still worse than the modest blunting effect.

When to Get Your Shot

Because protection wanes, timing your vaccination to coincide with peak flu season makes intuitive sense. But predicting when flu will peak in any given year is genuinely difficult. A modeling study explored how optimal vaccination timing shifts depending on the speed of waning and the timing of the season’s peak. When protection wanes quickly, delaying vaccination benefited all age groups regardless of when the season peaked. When protection wanes slowly, the picture was mixed: for older adults with high initial vaccine effectiveness in an early-peaking season, getting vaccinated early was better, but in late-peaking seasons, delaying vaccination prevented the most cases.¹⁸

In practice, most public health agencies recommend vaccination by the end of October in the Northern Hemisphere as a reasonable compromise, since flu activity most often peaks between December and February. Getting vaccinated too early, say in August, risks meaningful waning by late winter. Getting vaccinated too late risks catching the flu before your immune response has fully developed, which takes about two weeks. If you missed the early window, getting vaccinated in November or even December is still worthwhile, especially in seasons that peak late.

Vaccine Type and Durability

Most flu vaccines given to adults are standard-dose inactivated vaccines, either egg-based or cell-based. Over multiple seasons, egg-based and cell-based versions provided broadly similar overall levels of protection against confirmed outpatient flu.¹⁹ However, a separate analysis found that the cell-based version was about 10 to 15 percent relatively more effective than the egg-based version in some seasons, possibly because egg-adaptation can subtly alter the vaccine virus in ways that reduce the match to circulating strains.²⁰ Neither formulation has been shown to wane meaningfully faster or slower than the other within a single season.

The nasal spray vaccine (live attenuated influenza vaccine, or LAIV) works differently. Instead of injecting inactivated virus into muscle, it introduces a weakened live virus into the nose, stimulating a mucosal immune response involving a type of antibody called IgA that sits in the lining of the respiratory tract.²¹ In theory, mucosal immunity could be more relevant for blocking an infection that enters through the nose and throat. Early-stage research on next-generation nasal vaccines, including adenovirus-vectored approaches, has shown that they can produce both mucosal and systemic immune responses, with neutralizing antibodies remaining stable for at least six months in early trials.²² Whether that dual-pronged response translates into slower waning in real-world effectiveness has not yet been established in large populations.

The Push for a Longer-Lasting Vaccine

The fact that current flu vaccines essentially expire within a single season has driven decades of work toward a “universal” flu vaccine, one that would protect against multiple strains for years rather than months. Most universal vaccine strategies target the stem region of the hemagglutinin protein on the flu virus surface, because that region changes much less from year to year than the head region that current vaccines focus on. In animal studies, a vaccine candidate displaying a trimmed-down version of the hemagglutinin stem on rigid nanoparticle-like carriers induced strong, long-lasting immune responses and protected mice against both matched and mismatched H1N1 strains, even after a single dose.²³ Several universal vaccine candidates, including some based on mRNA technology, are now in human clinical trials, though none has yet been licensed. A vaccine that could extend meaningful protection to two or three years and cover multiple subtypes would fundamentally change the economics and logistics of flu prevention, but the field has been promising “five more years” for a long time.

For now, the annual shot remains the standard. Its protection is real but temporary, strongest in the first couple of months and diminishing steadily thereafter. Matching your vaccination timing to the expected flu peak, choosing a high-dose formulation if you are over 65, and not skipping years out of concern about repeat-vaccination effects are the most practical ways to get the most mileage out of each season’s vaccine.